<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03293485</url>
  </required_header>
  <id_info>
    <org_study_id>7655A-017</org_study_id>
    <secondary_id>173738</secondary_id>
    <nct_id>NCT03293485</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Imipenem+Cilastatin/Relebactam (MK-7655A) in Japanese Participants With Complicated Intra-abdominal Infection or Complicated Urinary Tract Infection (MK-7655A-017)</brief_title>
  <official_title>A Phase III Non-randomized, Non-controlled, Open Label Clinical Trial to Study the Safety and Efficacy of Imipenem/Cilastatin/Relebactam (IMI/REL [MK-7655A]) in Japanese Subjects With Complicated Intra-Abdominal Infection (cIAI) or Complicated Urinary Tract Infection (cUTI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will evaluate the efficacy and safety of imipenem+cilastatin/relebactam (IMI/REL,
      MK-7655A) in Japanese participants with complicated intra-abdominal infection (cIAI) or
      complicated urinary tract infection (cUTI).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 4, 2017</start_date>
  <completion_date type="Anticipated">November 9, 2018</completion_date>
  <primary_completion_date type="Anticipated">November 9, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>The percentage of participants with one or more adverse events will be assessed</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Discontinuations Due to an Adverse Event</measure>
    <time_frame>Up to 14 days (End of Therapy Visit)</time_frame>
    <description>The percentage of participants discontinued from study medication due to an adverse event will be assessed</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Favorable Clinical Response at End of Therapy Visit</measure>
    <time_frame>14 days (End of Therapy Visit)</time_frame>
    <description>The percentage of cIAI participants with favorable clinical response at the End of Therapy visit will be assessed</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Favorable Overall Microbiological Response at End of Therapy Visit</measure>
    <time_frame>14 days (End of Therapy Visit)</time_frame>
    <description>The percentage of cUTI participants with favorable Overall Microbiological Response at the End of Therapy visit will be assessed</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Favorable Clinical Response at Test of Cure Visit</measure>
    <time_frame>23 days (Test of Cure Visit)</time_frame>
    <description>The percentage of cIAI participants with favorable Clinical Response at the Test of Cure visit will be assessed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Favorable Overall Microbiological Response at Test of Cure Visit</measure>
    <time_frame>23 days (Test of Cure Visit)</time_frame>
    <description>The percentage of cUTI participants with favorable Overall Microbiological Response at the Test of Cure visit will be assessed</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Complicated Intra-abdominal Infection</condition>
  <condition>Complicated Urinary Tract Infection</condition>
  <arm_group>
    <arm_group_label>Imipenem+Cilastatin/Relebactam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with cIAI or cUTI will receive imipenem+cilastatin/relebactam intravenous (IV) infusion once every 6 hours for 5 to 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imipenem+Cilastatin/Relebactam</intervention_name>
    <description>Imipenem+Cilastatin/Relebactam 200/100 mg to 500/250 mg, depending on renal function, 30-minute IV infusion once every 6 hours</description>
    <arm_group_label>Imipenem+Cilastatin/Relebactam</arm_group_label>
    <other_name>IMI/REL</other_name>
    <other_name>MK-7655A</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  requires hospitalization and treatment with IV antibiotic therapy for complicated
             intraabdominal infection (cIAI) or complicated urinary tract infection (cUTI).
             Per-protocol diagnostic criteria apply to the qualifying infection types.

          -  infection is known or thought to be caused by microorganisms susceptible to the IV
             study therapy

          -  baseline specimen for primary infection site culture obtained at operative procedure
             in Screening period or at Baseline for cIAI participants, and within 48 hours before
             initiation of IV study drug for cUTI participants

          -  female or male who is not of reproductive potential, or female or male who is of
             reproductive potential and agrees to avoid becoming pregnant or impregnating a partner
             from the time of consent through completion of the study, by practicing abstinence
             from heterosexual activity or using acceptable contraception during heterosexual
             activity.

        Exclusion Criteria:

          -  received any amount of effective antibiotic therapy after obtaining the culture for
             admission to the study and before administration of the first dose of IV study therapy

          -  received treatment with systemic effective antibiotics for &gt;24 hours within the 72
             hours before initiation of study therapy

          -  has a concurrent infection, including endocarditis, osteomyelitis, meningitis, or
             prosthetic joint infection, that would interfere with evaluation of response to
             IMI/REL

          -  has a cIAI or cUTI due to a confirmed fungal pathogen

          -  has a cUTI that meets any of the following: 1) complete obstruction of any portion of
             the urinary tract, 2) known ileal loop, 3) intractable vesico-ureteral reflux, 4)
             presence of indwelling urinary catheter which cannot be removed at study entry

          -  has a cIAI that meets any of the following: 1) infection that should be managed by
             Staged Abdominal Repair (STAR) or open abdomen therapy, 2) infection limited to the
             hollow viscus

          -  history of serious allergy, hypersensitivity, or any serious reaction to any
             carbapenem, cephalosporin, penicillin or other beta-lactam agent, or other
             beta-lactamase inhibitors

          -  female who is pregnant or is expecting to conceive, is breastfeeding, or plans to
             breastfeed before completion of the study

          -  history of a seizure disorder

          -  anticipates to be treated with valproic acid, concomitant IV or an oral antimicrobial
             considered effective to the index pathogen, in addition to the study treatment

          -  is receiving immunosuppressive therapy, including high-dose corticosteroids

          -  is undergoing hemodialysis or peritoneal dialysis

          -  participated in any other clinical study involving an investigational or experimental
             medication during the previous 30 days before Screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
    <email>Trialsites@merck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Nagoya Ekisaikai Hospital ( Site 1724)</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>454-8502</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81526527711</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Toyota Memorial Hospital ( Site 1708)</name>
      <address>
        <city>Toyota</city>
        <state>Aichi</state>
        <zip>471-8513</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81565280100</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical Corporation Chiyukai Fukuoka Shin Mizumaki Hospital ( Site 1710)</name>
      <address>
        <city>Onga-gun</city>
        <state>Fukuoka</state>
        <zip>807-0051</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81932032220</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical Corporation Chiyukai Shin Yukuhashi Hospital ( Site 1722)</name>
      <address>
        <city>Yukuhashi</city>
        <state>Fukuoka</state>
        <zip>824-0026</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81930248899</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Fukuyama Medical Center ( Site 1706)</name>
      <address>
        <city>Fukuyama</city>
        <state>Hiroshima</state>
        <zip>720-8520</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81849220001</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fukuyama City Hospital ( Site 1721)</name>
      <address>
        <city>Fukuyama</city>
        <state>Hiroshima</state>
        <zip>721-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81849415151</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>KKR Sapporo Medical Center ( Site 1728)</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>062-0931</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81118221811</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sano Hospital ( Site 1701)</name>
      <address>
        <city>Kobe</city>
        <state>Hyogo</state>
        <zip>655-0031</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81787851000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Mito Medical Center ( Site 1729)</name>
      <address>
        <city>Higashiibaraki-gun</city>
        <state>Ibaraki</state>
        <zip>311-3193</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81292407711</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical Corporation Tokushukai Koga General Hospital ( Site 1712)</name>
      <address>
        <city>Koga</city>
        <state>Ibaraki</state>
        <zip>306-0041</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81280471010</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ishikawa Prefectural Central Hospital ( Site 1707)</name>
      <address>
        <city>Kanazawa</city>
        <state>Ishikawa</state>
        <zip>920-8530</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81762378211</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Kanazawa Medical Center ( Site 1716)</name>
      <address>
        <city>Kanazawa</city>
        <state>Ishikawa</state>
        <zip>920-8650</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81762624161</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kawahara Clinic ( Site 1719)</name>
      <address>
        <city>Aira</city>
        <state>Kagoshima</state>
        <zip>899-5431</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81995645181</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Yokohama Medical Center ( Site 1702)</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <zip>245-8575</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81458512621</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Mie Chuo Medical Center ( Site 1727)</name>
      <address>
        <city>Tsu</city>
        <state>Mie</state>
        <zip>514-1101</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81592591211</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Japan Labour Health And Safety Organization Tohoku Rosai Hospital ( Site 1714)</name>
      <address>
        <city>Sendai</city>
        <state>Miyagi</state>
        <zip>981-8563</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81222751111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Sendai Medical Center ( Site 1723)</name>
      <address>
        <city>Sendai</city>
        <state>Miyagi</state>
        <zip>983-8520</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81222931111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Suwa Red Cross Hospital ( Site 1705)</name>
      <address>
        <city>Suwa</city>
        <state>Nagano</state>
        <zip>392-8510</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81266526111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Nagasaki Medical Center ( Site 1718)</name>
      <address>
        <city>Omura</city>
        <state>Nagasaki</state>
        <zip>856-8562</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81957523121</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Osaka Minami Medical Center ( Site 1715)</name>
      <address>
        <city>Kawachinagano</city>
        <state>Osaka</state>
        <zip>586-8521</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81721535761</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Utsunomiya National Hospital ( Site 1711)</name>
      <address>
        <city>Utsunomiya</city>
        <state>Tochigi</state>
        <zip>329-1193</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81286732111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Minami Wakayama Medical Center ( Site 1725)</name>
      <address>
        <city>Tanabe</city>
        <state>Wakayama</state>
        <zip>646-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81739267050</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yamanashi Prefectural Central Hospital ( Site 1703)</name>
      <address>
        <city>Kofu</city>
        <state>Yamanashi</state>
        <zip>400-8506</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81552537111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fukuiken Saiseikai Hospital ( Site 1704)</name>
      <address>
        <city>Fukui</city>
        <zip>918-8503</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81776231111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical Corporation Chiyukai Fukuoka Wajiro Hospital ( Site 1709)</name>
      <address>
        <city>Fukuoka</city>
        <zip>811-0213</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81926080001</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical Corporation Shingenkai Kawahara Urological Clinic ( Site 1726)</name>
      <address>
        <city>Kagoshima</city>
        <zip>890-0073</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81992847117</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical Corporation Seifukai Yagi Clinic ( Site 1720)</name>
      <address>
        <city>Kagoshima</city>
        <zip>891-0105</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81992635558</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Kumamoto Medical Center ( Site 1713)</name>
      <address>
        <city>Kumamoto</city>
        <zip>860-0008</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81963536501</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Oita Medical Center ( Site 1717)</name>
      <address>
        <city>Oita</city>
        <zip>870-0263</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81975931111</phone>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 15, 2017</study_first_submitted>
  <study_first_submitted_qc>September 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 26, 2017</study_first_posted>
  <last_update_submitted>May 25, 2018</last_update_submitted>
  <last_update_submitted_qc>May 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Urinary Tract Infections</mesh_term>
    <mesh_term>Intraabdominal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imipenem</mesh_term>
    <mesh_term>MK-7655</mesh_term>
    <mesh_term>Cilastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

